<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1506222204
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2009
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        OSELTA 75MG CAPSULES
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OSELTAMIVIR
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        75
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        79.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J05AH02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Oselta&trade; is used for adults, adolescents, infants and children 1 year<br />old and older.<br />- Oselta&trade; is prescribed to you for treating flu (influenza). It can be<br />used when you have flu symptoms, and the flu virus is known to be<br />circulating in your community. Other times it may be used as listed<br />below.<br />- Oselta&trade; is prescribed for preventing flu. It can be used if you<br />have been in contact with someone who has flu. This is generally<br />decided on a case-by-case basis.<br />- Oselta&trade; is prescribed as preventive treatment in exceptional<br />cases. For example, it can be used when the seasonal flu vaccine<br />may not provide sufficient protection and when there is a flu<br />pandemic (global epidemic of flu).<br />- During a flu pandemic, Oselta&trade; can also be used to treat or<br />prevent flu in babies below 1 year of age. Doctors should make<br />decisions on whether to use Oselta&trade; in babies of this age, based on<br />the severity of the disease caused by the flu virus and the baby&rsquo;s<br />state of health, to ensure that the baby is likely to benefit from the<br />medicine.<br />- Oselta&trade; contains oseltamivir, which belongs to a group of<br />medicines named neuraminidase inhibitors. These medicines<br />prevent the flu virus from spreading inside the body. They help to<br />ease or prevent the symptoms of the flu virus infection.<br />- Influenza, usually called flu, is an infection caused by a virus. The<br />signs of flu often include a sudden fever (more than 37.8 &ordm;C),<br />cough, runny or stuffy nose, headaches, muscle aches and extreme<br />tiredness. These symptoms can also be caused by other infections.<br />True influenza infection only occurs during annual outbreaks<br />(epidemics) when flu viruses are spreading in the local community.<br />Outside epidemic periods, flu-like symptoms are usually caused by<br />a different type of infection or illness</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Oselta&trade;<br />- if you are allergic (hypersensitive) to oseltamivir or any of the<br />other ingredients of Oselta&trade; listed in section 6.<br />Warnings and precautions<br />Before you take Oselta&trade;, make sure your prescribing doctor knows<br />- if you are allergic to other medicines.<br />- if you have problems with your kidneys. If so, your dose may need<br />adjustment.<br />- if you have a severe medical condition, which may require<br />immediate hospitalisation.<br />- if your immune system is not working.<br />- if you have chronic heart disease or respiratory disease.<br />During treatment with Oselta&trade;, tell your prescribing doctor<br />- if you notice changes in behavior or mood (neuropsychiatric<br />events), especially in children and adolescents.<br />Oselta&trade; is not a flu vaccine<br />Oselta&trade; is not a vaccine: it treats infection, or prevents the flu virus<br />spreading. A vaccine gives you antibodies against the virus. Oselta&trade;<br />will not change the effectiveness of a flu vaccine, and you might be<br />prescribed both by your doctor.<br />Other medicines and Oselta&trade;<br />Tell your doctor or pharmacist if you are taking any other<br />medicines, or have recently taken any. This includes medicines<br />obtained without a prescription. The following medicines are<br />particularly important:<br />- chlorpropamide (used to treat diabetes)<br />- methotrexate (used to treat e.g. rheumatoid arthritis)<br />- phenylbutazone (used to treat pain and inflammation)<br />- probenecid (used to treat gout)<br />Pregnancy and breast-feeding<br />You must tell your doctor if you are pregnant, if you think you are<br />pregnant or if you are trying to get pregnant so that your doctor can<br />decide if Oselta&trade; is right for you.<br />The effects on breast fed infants are unknown. You must tell your<br />doctor if you are breast-feeding so that your doctor can decide if<br />Oselta&trade; is right for you.<br />Ask your doctor or pharmacist for advice before taking this<br />medicine.<br />Driving and using machines<br />Oselta&trade; has no effect on your ability to drive or use machines.<br />Important information about some of the ingredients of Oselta&trade;<br />One of the ingredient Ludipress of this medicine contains lactose. If<br />you have been told that you cannot digest or tolerate some sugars,<br />talk to your doctor before taking Oselta&trade;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Take this medicine exactly as your doctor has told you. Check with<br />your doctor or pharmacist if you are not sure.<br />Take Oselta&trade; as soon as possible, ideally within the first two days of<br />the start of flu symptoms.<br />The recommended doses<br />For treating flu, take two doses daily. It is usually convenient to<br />take one dose in the morning and one in the evening. It is<br />important to complete the whole 5-day course, even if you start<br />to feel better quickly.<br />For preventing flu or after being exposed to an infected person,<br />take one dose daily for 10 days. It is best to take this in the<br />mornings with breakfast.<br />In special situations, such as widespread flu and for patients with a<br />weak immune system, treatment will continue for up to 6 weeks or<br />12 weeks.<br />You must use the amount of oral suspension prescribed by the<br />doctor. The recommended dose is based on the patient&rsquo;s body<br />weight.</p><p>Adults and adolescents 13 to 17 years old</p><p>&nbsp;</p><p>Body weight Treating flu Preventing flu<br />dose for 5 days dose for 10 days<br />40 kg or more 75 mg twice daily 75 mg once daily</p><p>Children 1 to 12 years old<br />Body weight Treating flu Preventing flu<br />dose for 5 days dose for 10 days<br />10 to 15 kg 30 mg twice daily 30 mg once daily<br />More than 15 kg and<br />up to 23 kg 45 mg twice daily 45 mg once daily<br />More than 23 kg and<br />up to 40 kg 60 mg twice daily 60 mg once daily<br />More than 40 kg 75 mg twice daily 75 mg once daily</p><p>Infants less than 1 year old<br />Giving Oselta&trade; to infants less than 1 year old should be based upon<br />the judgment of a doctor after considering the potential benefit<br />versus any potential risk to the infant. Only limited data is available<br />for infants less than 2 years old, and no data for infants less than 1<br />month old. See following table.</p><p>Age Treating flu Preventing flu<br />dose for 5 days dose for 10 days<br />3 to 12 months 3 mg/kg twice daily 3 mg/kg once daily<br />1 to 3 months 2.5 mg/kg twice daily 2.5 mg/kg once daily<br />0 to 1 month 2 mg/kg twice daily 2 mg/kg once daily&nbsp;mg/kg = mg per kilogram of infant body weight<br />Method of administration<br />Swallow the capsules whole with water. Do not break or chew the<br />capsules.<br />Oselta&trade; can be taken with or without food, although taking it with<br />food can reduce the chance of feeling or being sick (nausea or<br />vomiting).<br />If you need oseltamivir as a liquid (oral suspension) but it&rsquo;s not<br />available, you can make<br />Oselta&trade; suspension from these capsules. See Making Oselta&trade;<br />suspension at home for instructions.</p><p>If you take more Oselta&trade; than you should, stop taking Oselta&trade;<br />and contact your doctor or pharmacist immediately.<br />You might experience nausea, vomiting and/or dizziness.<br />If you forget to take Oselta&trade;<br />Do not take a double dose to make up for a forgotten capsule.<br />If you stop taking Oselta&trade;<br />There are no side effects when you stop OseltaTM. But if OseltaTM is<br />stopped earlier than your doctor told you, the symptoms of flu may<br />come back.<br />If you have any further questions on the use of this medicine, ask<br />your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although<br />not everybody gets them. Many of the side effects listed below may<br />also be caused by influenza.<br />The following serious side effects have been rarely reported since<br />oseltamivir has been marketed:<br />- Anaphylactic and anaphylactoid reactions: severe allergic<br />reactions, with face and skin swelling, itchy rashes, low blood<br />pressure and breathing difficulties.<br />- Hepatic disorders (fulminant hepatitis, hepatic function disorder<br />and jaundice): yellowing of the skin and white of the eyes, change<br />in stool colour, changes in behavior.<br />- Angioneurotic oedema: sudden onset of severe swelling of the<br />skin mainly around the head and neck area, including eyes and<br />tongue, with difficulties breathing.<br />- Stevens-Johnson syndrome and toxic epidermal necrolysis:<br />complicated, possibly life-threatening allergic reaction, severe<br />inflammation of the outer and possibly inner skin, initially with<br />fever, sore throat, and fatigue, skin rashes, leading to blisters,<br />peeling, shedding of larger areas of skin, possible breathing<br />difficulties and low blood pressure.<br />- Gastrointestinal bleeding: prolonged bleeding from the large<br />bowel or spitting up blood.<br />- Neuropsychiatric disorders, as described below.<br />If you notice any of these symptoms, get medical help<br />immediately.<br />The most frequently (very common and common) reported side<br />effects of Oselta&trade; are feeling or being sick (nausea, vomiting),<br />stomach ache, stomach upset, headache and pain. These side<br />effects mostly occur after the first dose of the medicine and will<br />usually stop as treatment continues. The frequency of these effects<br />is reduced if the medicinal product is taken with food.<br />Rare but serious effects: get medical help at once<br />(These may affect up to 1 in 1,000 people)<br />During Oselta&trade; treatment, rare events have been reported that<br />include:<br />- Convulsions and delirium, including altered level of<br />consciousness<br />- Confusion, abnormal behavior<br />- Delusions, hallucinations, agitation, anxiety, nightmares<br />These are reported primarily among children and adolescents and<br />often started suddenly and resolved rapidly. A few cases resulted in<br />self-injury, some with fatal outcome. Such neuropsychiatric events<br />have also been reported in patients with influenza who were not<br />taking OseltaTM.<br />- Patients, especially children and adolescents, should be closely<br />monitored for the behavioral changes described above.<br />- If you notice any of these symptoms, especially in younger<br />people, get medical help immediately.<br />Adults and adolescents 13 to 17 years old<br />Very common: may affect more than 1 in 10 people<br />- Headache. - Nausea.<br />Common: may affect up to 1 in 10 people<br />- Bronchitis - Cold sore virus - Cough<br />- Dizziness - Fever - Pain - Pain in limb<br />- Runny nose - Sleeping difficulties<br />- Sore throat - Stomach ache - Tiredness<br />- Upper abdominal fullness - Upper respiratory tract infections<br />(inflammation of the nose, throat and sinuses)<br />- Upset stomach - Vomiting.<br />Uncommon: may affect up to 1 in 100 people<br />- Allergic reactions - Altered level of consciousness<br />- Convulsion - Heart rhythm abnormalities<br />- Mild to severe liver function disorders<br />- Skin reactions (inflammation of the skin, red and itchy rash,<br />scaling skin).<br />Rare: may affect up to 1 in 1,000 people<br />- Thrombocytopenia (low platelet count) - Visual disturbances.<br />Children 1 to 12 years old<br />Very common: may affect more than 1 in 10 people<br />- Cough - Nasal congestion - Vomiting.<br />Common: may affect up to 1 in 10 people<br />- Conjunctivitis (red eyes and discharge or pain in the eye)<br />- Ear inflammation and other ear disorders - Headache - Nausea<br />- Runny nose - Stomach ache - Upper abdominal fullness<br />- Upset stomach.<br />Uncommon: may affect up to 1 in 100 people<br />- Inflammation of the skin<br />- Tympanic membrane (eardrum) disorder.<br />Infants 1 to 12 months old<br />The reported side effects in infants 1 to 12 months old are similar<br />to the side effects reported for older children (1 year old or older).<br />Infants 0 to 1 month old<br />There is no information available for the use of Oselta&trade; in infants<br />less than 1 month old.<br />If any of the side effects get serious, or if you notice any side<br />effects not listed in this leaflet, tell your doctor or pharmacist.<br />However,<br />- if you or your child are repeatedly sick, or<br />- if the influenza symptoms get worse or the fever continues<br />Tell your doctor as soon as possible.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Keep out of the reach and sight of children.<br />- Do not store above 30 &ordm;C.<br />- Do not use Oselta&trade; after the expiry date which is stated on the<br />pack after EXP.<br />Medicines should not be disposed of via wastewater or household<br />waste. Ask your pharmacist how to dispose of medicines no longer<br />required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Oselta&trade; contains<br />- The active substance is oseltamivir.<br />- Each hard capsule contains oseltamivir phosphate equivalent to<br />75 mg of oseltamivir.<br />- The other ingredients are Colloidal silicon dioxide,<br />Croscarmellose sodium, Ludipress, Povidone K30, Pregelatinised<br />starch, Talc, Sunset yellow (FD&amp;C yellow No.6), Quinoline yellow<br />(D&amp;C yellow No.10), Titanium dioxide and Gelatin<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What OseltaTM looks like and contents of the pack
- Oselta™ capsules are yellow opaque cap and off-white opaque
body, hard gelatin capsules filled with white to off white
homogenous powder.
- Oselta™ 75 mg capsules are available in a box of 10 capsules.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder and Manufacturer<br />Jamjoom Pharmaceuticals Co., Ltd., Jeddah, Saudi Arabia.<br />Tel: +966-12-6081111, Fax: +966-12-6081222.<br />Website: www.jamjoompharma.com<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222,<br />Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa. Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 02/2013; Version number 01.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>للبالغين، المراهقين، الأطفال و الرضع الذين تبلغ أعمارهم سنة واحدة &trade; &bull; تستخدم أوسلتا<br />أو أكثر.<br />عندما تظهر &trade; لك لعلاج الإنفلونزا. يُمكن أن تستخدم أوسلتا &trade; &bull; لقد تم وصف أوسلتا<br />عليك أعراض الإنفلونزا إذا كانت الإصابة بفيرس الإنفلونزا من المعروف أنها شائعة فى<br />على النحو الوارد أدناه . &trade; مجتمعك. فى بعض الأوقات الأخرى يمكن استخدام أوسلتا<br />للوقاية من الإنفلونزا و ذلك عند اختلاطك بشخص ما مصاب &trade; &bull; تستخدم أوسلتا<br />بالإنفلونزا.<br />كعلاج وقائى فى بعض الحالات الاستثنائية . على سبيل المثال ، &trade; &bull; يتم وصف أوسلتا<br />يمكن استخدامه عندما لا يوفر لقاح الإنفلونزا الموسمية الحماية الكافية أو عند تفشى<br />الإنفلونزا بصورة وبائية (وباء الإنفلونزا العالمى).<br />لعلاج أو للوقاية من &trade; &bull; أثناء تفشى الإنفلونزا بصورة وبائية، يمكن أن تستخدم أوسلتا<br />الإنفلونزا لدى الرضع الذين يقل عمرهم عن سنة واحدة. يجب أن يقرر الطبيب استخدام<br />هذا الدواء للأطفال فى هذه المرحلة من العمر بناءا على شدة المرض الناتج عن الإصابة<br />بفيرس الإنفلونزا و حالة الطفل الصحية للتأكد من أن الطفل قد يستفيد من هذا الدواء.<br />يحتوى على أوسلتاميڤير الذى ينتمى إلى مجموعة من الأدوية تسمى &quot;مثبطات &trade; &bull; أوسلتا<br />النيورامينيداز&quot;. هذه الأدوية تمنع انتشار ڤيرس الإنفلونزا داخل الجسم كما تساعد فى<br />تخفيف أو منع أعراض عدوى ڤيرس الإنفلونزا.<br />&bull; الإنفلونزا هى عدوى يسببها ڤيرس. أعراض الإصابة بالإنفلونزا غالبا ما تشمل ارتفاع<br />مفاجىء فى درجة الحرارة (أكثر من ۳۷,۸ درجة سيلزية )، سعال، رشح أو انسداد<br />الأنف، صداع، آلام العضلات و التعب الشديد. هذه الأعراض قد تكون ناتجة أيضا عن<br />الإصابة بأى عدوى أخرى. الإنفلونزا الحقيقية تحدث فقط أثناء التفشى السنوى للإنفلونزا<br />(الإنتشار الوبائى للإنفلونزا) عندما تنتشر ڤيروسات الإنفلونزا فى المجتمع المحلى. خارج<br />أوقات الإنتشار الوبائى للإنفلونزا عادة ما تكون أعراض الإنفلونزا ناتجة عن الإصابة<br />بنوع آخر من العدوى أو الأمراض.<br />.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>۲. ما الذى تحتاج لمعرفته قبل أن تتناول أوسلتا<br />فى الحالات الآتية: &trade; لا تتناول أوسلتا<br />و &trade; &bull; إذا كنت تعانى حساسية مفرطة لأوستاميڤير أو أى من المكونات الأخرى لأوسلتا<br />. المذكورة فى الجزء رقم ٦<br />تحذيرات و إحتياطات وقائية:<br />تأكد من أن طبيبك يعلم الآتى: ،&trade; قبل أن تتناول أوسلتا<br />&bull; إذا كنت تعانى من حساسية لبعض الأدوية الأخرى .<br />&bull; إذا كنت تعانى مشاكل فى الكلى لأن فى هذه الحالة فأنت بحاجة إلى تعديل جرعتك.<br />&bull; إذا كنت تعانى من مشكلة مرضية خطيرة و التى قد تتطلب العلاج الفورى فى<br />المستشفى.<br />&bull; إذا كان جهازك المناعى لا يعمل بشكل سليم.<br />&bull; إذا كنت تعانى من مرض مزمن فى القلب أو فى الجهاز التنفسى.<br />أخبر طبيبك فى الحالات الآتية: ،&trade; أثناء علاجك بأوسلتا<br />&bull; إذا لاحظت تغير فى السلوك أو المزاج (الأحداث النفسية العصبية) ، خاصة عند الأطفال<br />و المراهقين.<br />ليس لقاح للإنفلونزا. &trade; أوسلتا<br />ليس لقاح للإنفلونزا لكنه يعالج أو يمنع انتشار ڤيرس الإنفلونزا. لقاح الإنفلونزا &trade; أوسلتا<br />لا يغير من فاعلية لقاح الإنفلونزا و قد يصف &trade; يمنحك أجسام مضادة ضد الڤيرس. أوسلتا<br />معا. &trade; لك طبيبك كلا من اللقاح و أوسلتا<br />تناول أدوية أخرى<br />يرجى إخبار الطبيب أو الصيدلى إذا كنت تتناول أو أخذت مؤخرا أي أدوية أخرى. هذا<br />يشمل الأدوية التى يمكنك شراؤها بدون تذكرة طبية. الأدوية الآتية من المهم بشكل خاص<br />أن تخبر بها طبيبك:<br />&bull; كلوروبروباميد (يستخدم لعلاج داء السكرى).<br />&bull; ميثوتريكسات (يستخدم لعلاج التهاب المفاصل الروماتويدى).<br />&bull; فينيل بيوتازون (يستخدم لعلاج الألم و الالتهاب).<br />&bull; بروبنسيد (يستخدم لعلاج النقرص).<br />الحمل و الرضاعة<br />يجب أن تخبرى طبيبك فى حالة كونك حامل ، تخططين أن تكونى حامل أو تشكين فى<br />مناسب لكى. &trade; كونك حامل ، لكى يقرر طبيبك ما إذا كان استخدام أوسلتا<br />التأثيرات الواقعة على الأطفال الرضع غير معروفة، يجب أن تخبرى طبيبك إذا كنتِ<br />مناسب لكى. &trade; مرضعة لكى يقرر طبيبك ما إذا كان استخدام أوسلتا<br />استشيرى الطبيب أو الصيدلى قبل أن تتناولى هذا الدواء.<br />قيادة المركبات و تشغيل الآلات<br />لا يؤثر فى قدرتك على القيادة و تشغيل الآلات. &trade; أوسلتا<br />&trade; معلومة هامة عن بعض المكونات الموجودة فى أقراص أوسلتا<br />أحد مكونات هذا الدواء ليودبريس يحتوى على اللاكتوز. إذا قيل لك أنه لا يمكنك هضم أو<br />.&trade; تحمل بعض السكريات ، أخبر طبيبك بهذا قبل البدء فى تناول أوسلتا</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>۳. كيف تتناول أوسلتا<br />كما أخبرك طبيبك تماما. يجب عليك مراجعة الطبيب أو الصيدلى &trade; قم دائما بأخذ أوسلتا<br />إذا كنت غير متأكد من طريقة الاستخدام .<br />فى أسرع وقت ممكن و يُفضّل أن يؤخذ خلال أول يومين من بداية &trade; قم بأخذ أوسلتا<br />ظهور أعراض الإنفلونزا.<br />الجرعات الموصى بها<br />لعلاج الإنفلونزا ، خذ جرعتين يوميا. عادة ما يكون من المناسب أن تتناول جرعة فى<br />الصباح و جرعة أخرى فى المساء. من المهم أن تُكمل دورة العلاج التى تبلغ مدتها<br />٥ أيام حتى إذا بدأت تشعر بالتحسن بشكل سريع.<br />للوقاية من الإنفلونزا أو بعد الإختلاط بشخص مصاب بالإنفلونزا ، خذ جرعة واحدة يوميا<br />لمدة ۱۰ أيام. من الأفضل أن تتناولها فى الصباح مع الإفطار.<br />فى بعض الحالات الخاصة مثل تفشى الإنفلونزا و للأشخاص الذين يعانون من ضعف<br />المناعة ، سوف يستمر العلاج لمدة تصل إلى ٦ أو ۱۲ أسبوع.<br />البالغين و المراهقين الذين تتراوح أعمارهم بين ۱۳ إلى ۱۷ عام</p><p>البالغين و المراهقين الذين تتراوح أعمارهم بين ۱۳ إلى ۱۷ عام</p><p>وزن الجسم لعلاج الإنفلونز ا للوقاية من الإنفلونزا<br />مدة العلاج ٥ أيام مدة العلاج ۱۰ أيام<br />٤۰ كجم أو أكثر ۷٥ مجم مرتين يومي ا ۷٥ مجم مرة يوميا</p><p>الأطفال من عمر ۱ إلي ۱۲ سنة</p><p>وزن الجسم لعلاج الإنفلونز ا للوقاية من الإنفلونزا<br />مدة العلاج ٥ أيام مدة العلاج ۱۰ أيام<br />۱۰ إلى ۱٥ كجم ۳۰ مجم مرتين يوميا ۳۰ مجم مرة واحدة يوميا<br />أكثر من ۱٥ كجم<br />وحتى ۲۳ كجم ٤٥ مجم مرتين يوميا ٤٥ مجم مرة واحدة يوميا<br />أكثر من ۲۳ كجم<br />وحتى ٤۰ كجم ٦۰ مجم مرتين يوميا ٦۰ مجم مرة واحدة يوميا<br />أكثر من ٤۰ كجم ۷٥ مجم مرتين يوميا ۷٥ مجم مرة واحدة يوميا</p><p>الرضع أقل من عام<br />للرضع أقل من ۱ سنة من العمر على حكم الطبيب بعد &trade; وينبغي أن يستند إعطاء أوسلتا<br />النظر في الفوائد المحتملة<br />مقابل أي خطر محتمل على الرضيع. هو فقط بيانات محدودة متاحة للأطفال الرضع أقل<br />من ۲ سنة، ولا يوجد بيانات للرضع أقل من عمر ۱ شهر. انظر الجدول التالي.</p><p>العمر لعلاج الإنفلونزا للوقاية من الإنفلونزا<br />مدة العلاج ٥ أيام مدة العلاج ۱۰ أيام<br />من ۳ إلى ۱۲ شهر ۳ مجم/ كجم مرتين يوميا ۳ مجم/ كجم مرة يوميا<br />من شهر إلى ۳ أشهر ۲٫٥ مجم/ كجم مرتين يوميا ۲٫٥ مجم/ كجم مرة يوميا<br />من يوم إلى شهر ۲ مجم/ كجم مرتين يوميا ۲ مجم/ كجم مرة يوميا</p><p>مجم/ كج = مجم لكل كيلوجرام من وزن الرضيع.<br />طريقة تناول الدواء<br />قم ببلع الكبسولات كاملة مع الماء.<br />مع الطعام يقلل من &trade; مع أو بدون الطعام، لكن تناول أوسلتا &trade; يمكن استخدام أوسلتا<br />الشعور بالغثيان و القىء.<br />إذا كنت فى حاجة إلى أوسلتاميڤير فى صورة سائل و لكن لا تستطيع الحصول عليه ،<br />باستخدام هذه الكبسولات. انظر الى الجزء الذى يحمل عنوان &trade; يمكنك صنع معلّق أوسلتا<br />فى المنزل&quot;. &trade; &quot;صنع معلق أوسلتا<br />و قم بالآتى : &trade; أكثر مما ينبغى ، توقف عن تناول أوسلتا &trade; إذا كنت تتناول أوسلتا<br />اتصل على الفور بالطبيب أو الصيدلى.<br />قد تشعر بالغثيان، القىء و/ أو الدوار.<br />&trade; إذا نسيت أن تتناول أوسلتا<br />لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية.<br />&trade; إذا توقفت عن تناول أوسلتا<br />لكن إذا توقفت قبل أن يخبرك طبيبك .&trade; لا توجد أعراض جانبية للتوقف عن تناول أوسلتا<br />بهذا ، ربما تعود أعراض الإنفلونزا مرة أخرى.<br />إذا كان لديك أية أسئلة أخرى عن استخدام هذا الدواء ، إسأل الطبيب أو الصيدلى</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>لكنها لا &trade; كما هو الحال مع جميع الأدوية، من المحتمل ظهور أعراض جانبية لأوسلتا<br />تصيب كل الأشخاص. العديد من الآثار الجانبية المذكورة بالأسفل قد تحث أيضا نتيجة<br />الإصابة بالإنفلونزا.<br />الأعراض الجانبية الخطيرة الآتية قد تم الإبلاغ عن حدوثها بشكل نادر منذ أن تم تسويق<br />أوسلتاميڤير:<br />&bull; التفاعل التأقى و التفاعل شبة التأقى: رد فعل تحسسى شديد مع تورم الوجه و الجلد ،<br />طفح جلدى مثير للحكة، انخفاض ضغط الدم و صعوبة فى التنفس.<br />&bull; إضطرابات الكبد مثل التهاب الكبد الخاطف ، إضطراب وظائف الكبد و اليرقان :<br />إصفرار الجلد و بياض العين ، تغير لون البراز و تغير السلوك.<br />&bull; وذمة وعائية عصبية: تورم حاد و مفاجىء فى الجلد حول الرأس و فى منطقة الرقبة<br />ويشمل العينين و اللسان مع صعوبة فى التنفس.</p><p>&bull; متلازمة ستيڤينز جونسون و انحلال البشرة السمى: رد فعل تحسسى معقد و ربما يكون<br />مهدد للحياة يسبب التهاب شديد للجلد الخارجى وربما الداخلى أيضا يبدأ بالحمى ، التهاب<br />الحلق ، التعب، طفح جلدى يؤدى الى تقرح و تقشر أجزاء كبيرة من الجلد و قد يحدث<br />صعوبة فى التنفس و انخفاض فى ضغط الدم.<br />&bull; نزيف الجهاز الهضمى: النزيف لفترة طويلة من الأمعاء الغليظة أو بصق الدم.<br />&bull; الإضطرابات العصبية النفسية: كما هو موضّح أدناه.<br />إذا لاحظت حدوث أى من الأعراض الجانبية الآتية، يرجى استشارة الطبيب على الفور:<br />هى الشعور بالغثيان ، &trade; الآثار الجانبية الأكثر حدوثا (شائعة أو شائعة جدا) مع أوسلتا<br />القىء، ألم المعدة، إضطراب المعدة، صداع و الألم. عادة ما تحدث هذه الآثار الجانبية بعد<br />الجرعة الأولى من الدواء و غالبا ما تتوقف مع الإستمرار فى تناول الدواء . يقل معدل<br />تكرار هذه الآثار إذا ما أُخذ هذا الدواء مع الطعام.<br />أعراض جانبية نادرة و لكن خطيرة ، اطلب المساعدة الطبية فى الحال عند حدوث<br />الآتى:<br />(تصيب ۱ من كل ۱۰۰۰ شخص يستخدمون هذا الدواء)<br />&bull; تشنجات و هذيان و تغير مستوى الوعى.<br />&bull; تشوش و تغير فى السلوك.<br />&bull; تهيؤات ، هلوسة، تهيج، قلق، كوابيس .<br />هذه الأعراض تم الإبلاغ عن حدوثها بشكل أساسى عند الأطفال و المراهقين و غالبا ما<br />تبدأ فى الحدوث فجأة و تزول سريعا. فى بعض الحالات القليلة ، أسفرت هذه الأعراض<br />عن جرح الذات مع بعض النتائج المميتة.<br />المرضى خاصة الأطفال و المراهقين يجب ملاحظتهم عن قرب لرصد التغييرات<br />السلوكية المذكورة أعلاه.<br />إذا لاحظت أى من هذه الآثار الجانبية خاصة لدى المرضى صغار السن ، اطلب<br />المساعدة الطبية على الفور.<br />البالغين و المراهقين الذين تتراوح أعمارهم بين ۱۳ إلى ۱۷ عام<br />أعراض جانبية شائعة جدا ( تصيب أكثر من ۱ من كل ۱۰ أشخاص يستخدمون هذا<br />الدواء)<br />&bull; صداع. &bull; غثيان.<br />أعراض جانبية شائعة ( تصيب ۱ من كل ۱۰ أشخاص يستخدمون هذا الدواء)<br />&bull; التهاب الشعب الهوائية. &bull; ڤيرس قرح البرد. &bull; سعال.<br />&bull; دوار. &bull; حمى. &bull; ألم.<br />&bull; ألم الأطراف. &bull; رشح الأنف. &bull; صعوبة فى النوم.<br />&bull; التهاب الحلق. &bull; آلام فى المعدة. &bull; الإرهاق.<br />&bull; الشعور بإمتلاء البطن. &bull; عدوى الجهاز التنفسى العلوى (التهاب الأنف،<br />الحلق و الجيوب الأنفية). &bull; إضطراب المعدة. &bull; قىء.<br />أعراض جانبية غير شائعة ( تصيب ۱ من كل ۱۰۰ شخص يستخدمون هذا الدواء)<br />&bull; حساسية. &bull; تغير مستوى الوعى. &bull; تشنجات.<br />&bull; إضطرابات فى إيقاع القلب. &bull; إضطرابات متوسطة إلى حادة فى وظائف الكبد.<br />&bull; تفاعلات جلدية تشمل التهاب الجلد، طفح جلدى أحمر اللون مثير للحكة ، تقشر الجلد.<br />أعراض جانبية نادرة ( تصيب ۱ من كل ۱۰۰۰ أشخاص يستخدمون هذا الدواء)<br />&bull; نقص الصفيحات (انخفاض عدد الصفائح الدموية) &bull; إضطرابات بصرية.<br />الأطفال من عمر عام إلى ۱۲ عام<br />أعراض جانبية شائعة جدا ( تصيب أكثر من ۱ من كل ۱۰ أشخاص يستخدمون هذا<br />الدواء)<br />&bull; سعال. &bull; احتقان الأنف. &bull; قىء.<br />أعراض جانبية شائعة ( تصيب ۱ من كل ۱۰ أشخاص يستخدمون هذا الدواء)<br />&bull; التهاب ملتحمة العين مما يسبب إحمرار العينين، خروج إفرازات من العين أو ألم<br />العينين.<br />&bull; التهاب الأذن و مشاكل الأذن الأخرى. &bull; صداع. &bull; غثيان.<br />&bull; رشح الأنف. &bull; ألم المعدة.<br />&bull; الشعور بإمتلاء البطن. &bull; إضطراب المعدة.<br />أعراض جانبية غير شائعة ( تصيب ۱ من كل ۱۰۰ أشخاص يستخدمون هذا الدواء)<br />&bull; التهاب الجلد. &bull; إضطراب غشاء طبلة الأذن.<br />الرضع من عمر شهر إلى ۱۲ شهر<br />الأعراض الجانبية التى تم الإبلاغ عنها فى الرضع من عمر شهر إلى ۱۲ شهر تكون<br />شبيهه بالأعراض الجانبية التى تم الإبلاغ عنها فى الأطفال الأكبر سنا (الأطفال من عمر<br />عام و أكبر).<br />الرضع أقل من شهر<br />فى الرضع الذين تقل أعمارهم عن شهر &trade; لا توجد معلومات متوفرة عن استخدام أوسلتا<br />واحد.<br />إذا وصلت أحد الآثار الجانبية لهذا الدواء لمرحلة الخطر أو ظهرت آثار جانبية جديدة لم<br />تذكر في هذه النشرة يرجى اخبار الطبيب أو الصيدلي.<br />إذا مرضت أو مرض طفلك بشكل متكرر أو إذا أزدادت أعراض الإنفلونزا سوءا أو<br />استمرت الحمى ، يرجى اخبار الطبيب على الفور.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيداً عن متناول و مرأي الأطفال.<br />يحفظ فى درجة حرارة لا تزيد عن ۳۰ درجة مئوية.<br />لا تتناول هذا الدواء بعد انتهاء فترة الصلاحية المكتوبة على العلبة وعلى الشرائط.<br />اسأل الصيدلي عن طريقة التخلص من الأدوية التي لم تعد بحاجة إليها. لا ينبغي التخلص<br />من الأدوية عبر إلقائها فى بالوعات الصرف أو فى مخلفات المنزل . ستساعد هذه التدابير<br />في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ما هي مكونات أوسلتا<br />كل كبسولة صلبة تحتوى على أوسلتاميڤير فوسفات يعادل ۷٥ مجم أوسلتاميڤير .<br />المكونات الأخرى هي: ثانى أكسيد السيليكون الغروي،كروسكارميللوز الصوديوم،<br />FD&amp;C ) ليوديبرس، بوفيدون، نشا مسبق التجلتن، تلك، أصفرغروب الشمس الصفراء<br />أصفر رقم ۱۰ ) وثاني أكسيد التيتانيوم. D &amp; C) أصفر رقم ٦)، أصفر الكينولين</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>٥ مجم كبسولات جيلاتينية صلبة غير شفافة غطائها أصفر و جسمها أبيض، &trade; أوسلتا<br />مليئة بمسحوق متجانس أبيض إلي مائل للأبيض.<br />۷٥ مجم كبسولات صلبة متوفرة فى شكل شرائط كل منها يحتوى على ۱۰ &trade; أوسلتا<br />أقراص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>اسم وعنوان مالك رخصة التسويق و المصنع:<br />شركة مصنع جمجوم للأدوية المحدودة،<br />جدة، المملكة العربية السعودية<br />+۹٦٦-۱۲- ۹٦٦ + فاكس: ٦۰۸۱۲۲۲ -۱۲- الهاتف: ٦۰۸۱۱۱۱<br />www.jamjoompharma.com : الموقع الإلكتروني<br />للإبلاغ عن أي أثار جانبيه:<br />&bull; المملكة العربية السعودية:<br />المركز الوطني للتيقظ و السلامة الدوائية<br />+۹٦٦-۱۱-۲۰٥- فاكس: ۷٦٦۲<br />للإتصال بالإدارة التنفيذية للتيقظ وإدارة الأزمات.<br />+۹٦٦-۱۱- هاتف: ۲۰۳۸۲۲۲۲<br />۲۳٤۰-۲۳۳٤-۲۳٥٤-۲۳٥۳-۲۳٥٦- تحويلة: ۲۳۱۷<br />الهاتف المجاني: ۸۰۰۲٤۹۰۰۰۰<br />npc.drug@sfda.gov.sa : بريد إلكتروني<br />www.sfda.gov.sa/npc : الموقع الالكتروني<br />&bull; دول الخليج الأخرى:<br />الرجاء الاتصال بالمؤسسات و الهيئات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ۲۰۱۳ . رقم النسخة ۰۱ / تم مراجعة هذه النشرة في ۰۲
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oselta 75 mg capsule
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each capsule contains Oseltamivir phosphate equivalent to 75 mg of Oseltamivir.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Capsule
Yellow opaque cap and off-white opaque body, size '2' hard gelatin capsules, filled with white to
off white homogenous powder, packed in Alu -PVC blister.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of influenza<br />In patients one year of age and older who present with symptoms typical of influenza, when<br />influenza virus is circulating in the community. Efficacy has been demonstrated when treatment is<br />initiated within two days of first onset of symptoms. This indication is based on clinical studies of<br />naturally occurring influenza in which the predominant infection was influenza A<br />Oselta is indicated for the treatment of infants less than 1 year of age during a pandemic influenza<br />outbreak<br />The treating physician should take into account the pathogenicity of the circulating strain and the<br />underlying condition of the patient to ensure there is a potential benefit to the child.<br />Prevention of influenza</p><p>- Post-exposure prevention in individuals 1 year of age or older following contact with a clinically<br />diagnosed influenza case when influenza virus is circulating in the community.<br />- The appropriate use of Oselta for prevention of influenza should be determined on a case by case<br />basis by the circumstances and the population requiring protection. In exceptional situations (e.g.<br />in case of a mismatch between the circulating and vaccine virus strains, and a pandemic situation)<br />seasonal prevention could be considered in individuals one year of age or older.<br />- Oselta is indicated for post-exposure prevention of influenza in infants less than 1 year of age<br />during a pandemic influenza outbreak<br />Oselta is not a substitute for influenza vaccination.<br />The use of antivirals for the treatment and prevention of influenza should be determined on the<br />basis of official recommendations. Decisions regarding the use of Oseltamivir for treatment and<br />prophylaxis should take into consideration what is known about the characteristics of the<br />circulating influenza viruses, available information on influenza drug susceptibility patterns for<br />each season and the impact of the disease in different geographical areas and patient populations</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Adults, and adolescents 13 years and over<br />Treatment: The recommended oral dose is 75 mg Oseltamivir twice daily for 5 days for<br />adolescents (13 to 17 years of age) and adults.<br />Body Weight Recommended dose for 5 days<br />&gt; 40 kg 75 mg twice daily</p><p>Treatment should be initiated as soon as possible within the first two days of onset of symptoms<br />of influenza.<br />Post-exposure prevention: The recommended dose for prevention of influenza following close<br />contact with an infected individual is 75 mg Oseltamivir once daily for 10 days for adolescents<br />(13 to 17 years of age) and adults.<br />Body Weight Recommended dose for 10 days<br />&gt; 40 kg 75 mg once daily<br />Therapy should begin as soon as possible within two days of exposure to an infected individual.<br />Prevention during an influenza epidemic in the community: The recommended dose for<br />prevention of influenza during a community outbreak is 75 mg Oseltamivir once daily for up to 6<br />weeks.<br />Children 1 to 12 years<br />Oselta 30 mg, 45 mg and 75 mg capsules and oral suspension are available for infants and<br />children 1 year of age or older<br />Treatment: The following weight-adjusted dosing regimens are recommended for treatment of<br />infants and children 1 year of age or older:<br />Body Weight Recommended dose for 5 days<br />10 kg to 15 kg 30 mg twice daily<br />&gt; 15 kg to 23 kg 45 mg twice daily<br />&gt; 23 kg to 40 kg 60 mg twice daily</p><p>&gt; 40 kg 75 mg twice daily<br />Treatment should be initiated as soon as possible within the first two days of onset of symptoms<br />of influenza.<br />Post-exposure prevention: The recommended post-exposure prevention dose of Oselta is:<br />Body Weight Recommended dose for 10 days<br />10 kg to 15 kg 30 mg once daily<br />&gt; 15 kg to 23 kg 45 mg once daily<br />&gt; 23 kg to 40 kg 60 mg once daily<br />&gt; 40 kg 75 mg once daily<br />Prevention during an influenza epidemic in the community: Prevention during an influenza<br />epidemic has not been studied in children below 12 years of age.<br />For infants below 1 year of age<br />In the absence of a suitable formulation, a pharmacy compounded preparation should<br />preferentially be used as the syringe provided in the Oselta 12 mg/ml powder for oral suspension<br />pack (with mg markings) does not allow for appropriate dose adjustments and commercially<br />available syringes (with ml markings) may lead to unacceptable dosing inaccuracies.<br />Treatment: The recommended treatment dose for infants less than 1 year of age is between 2<br />mg/kg twice daily and 3 mg/kg twice daily during a pandemic influenza outbreak. This is based<br />upon limited pharmacokinetic and safety data indicating that these doses provide plasma drug<br />exposures in the majority of patients similar to those shown to be clinically efficacious in older<br />children and adults. The following&nbsp;age-adjusted dosing regimens are recommended for treatment<br />of infants below 1 year of age:</p><p>Age Recommended dose for 5 days<br />0 to 1 month* 2 mg/kg twice daily<br />&gt; 1 month to 3 months 2.5 mg/kg twice daily<br />&gt; 3 months to 12 months 3 mg/kg twice daily<br />* There is no data available regarding the administration of Oselta to infants less than one month<br />of age.<br />Treatment should be initiated as soon as possible within the first two days of onset of symptoms<br />of influenza.<br />These age-based dosing recommendations are not intended for premature infants, i.e. those with a<br />postmenstrual age less than 37 weeks. Insufficient data are available for these patients, in whom<br />different dosing may be required due to the immaturity of physiological functions.<br />Post-exposure prevention: The recommended prophylaxis dose for infants less than 1 year of age<br />during a pandemic influenza outbreak is half of the daily treatment dose. This is based upon<br />clinical data in infants and children 1 year of age or older and adults showing that a prophylaxis<br />dose equivalent to half the daily treatment dose is clinically efficacious for the prevention of<br />influenza. The following age-adjusted dosing prophylaxis regimens are recommended for infants<br />below 1 year of age:<br />Age Recommended dose for 10 days<br />0 to 1 month* 2 mg/kg once daily<br />&gt; 1 month to 3 months 2.5 mg/kg once daily<br />&gt; 3 months to 12 months 3 mg/kg once daily<br />* There is no data available regarding the administration of Oselta to infants less than one month</p><p>of age.<br />These age-based dosing recommendations are not intended for premature infants, i.e. those with a<br />postmenstrual age less than 37 weeks. Insufficient data are available for these patients, in whom<br />different dosing may be required due to the immaturity of physiological functions.<br />For instructions on preparing the extemporaneous formulation, see section 6.6.<br />Special populations<br />Hepatic impairment<br />No dose adjustment is required either for treatment or for prevention in patients with hepatic<br />dysfunction. No studies have been carried out in paediatric patients with hepatic disorder.<br />Renal impairment<br />Treatment of influenza: Dose adjustment is recommended for adults and adolescents (13 to 17<br />years of age) with moderate or severe renal impairment. Recommended doses are detailed in the<br />table below.<br />Creatinine clearance Recommended dose for treatment<br />&gt; 60 (ml/min) 75 mg twice daily<br />&gt; 30 to 60 (ml/min) 30 mg (suspension or capsules) twice daily<br />&gt; 10 to 30 (ml/min) 30 mg (suspension or capsules) once daily<br />&le; 10 (ml/min) Not recommended (no data available)<br />Haemodialysis patients 30 mg after each haemodialysis session<br />Peritoneal dialysis patients* 30 mg (suspension or capsules) single dose</p><p>* Data derived from studies in continuous ambulatory peritoneal dialysis (CAPD) patients; the<br />clearance of Oseltamivir carboxylate is expected to be higher when automated peritoneal dialysis<br />(APD) mode is used. Treatment mode can be switched from APD to CAPD if considered<br />necessary by a nephrologist.<br />Prevention of influenza: Dose adjustment is recommended for adults and adolescents (13 to 17<br />years of age) with moderate or severe renal impairment as detailed in the table below.<br />Creatinine clearance Recommended dose for prevention<br />&gt; 60 (ml/min) 75 mg once daily<br />&gt; 30 to60 (ml/min) 30 mg (suspension or capsules) once daily<br />&gt; 10 to 30 (ml/min) 30 mg (suspension or capsules) every second<br />day<br />&le; 10 (ml/min) Not recommended (no data available)<br />Haemodialysis patients 30 mg after every second haemodialysis<br />session<br />Peritoneal dialysis patients* 30 mg (suspension or capsules) once weekly<br />* Data derived from studies in continuous ambulatory peritoneal dialysis (CAPD) patients; the<br />clearance of Oseltamivir carboxylate is expected to be higher when automated peritoneal dialysis<br />(APD) mode is used. Treatment mode can be switched from APD to CAPD if considered<br />necessary by a nephrologist.<br />There is insufficient clinical data available in infants and children (12 years of age and younger)<br />with renal impairment to be able to make any dosing recommendation.<br />Elderly&nbsp;No dose adjustment is required, unless there is evidence of moderate or severe renal impairment.<br />Immunocompromised patients<br />Longer duration of seasonal prophylaxis up to 12 weeks has been evaluated in<br />immunocompromised patients<br />Method of administration<br />Oral use.<br />Adults, adolescents (13 to 17 years of age) or infants and children (1 year of age or older) who are<br />unable to swallow capsules may receive appropriate doses of Oselta suspension.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Oseltamivir is effective only against illness caused by influenza viruses. There is no evidence for<br />efficacy of Oseltamivir in any illness caused by agents other than influenza viruses.<br />Oselta is not a substitute for influenza vaccination. Use of Oselta must not affect the evaluation of<br />individuals for annual influenza vaccination. The protection against influenza lasts only as long as<br />Oselta is administered. Oselta should be used for the treatment and prevention of influenza only<br />when reliable epidemiological data indicate that influenza virus is circulating in the community.<br />Susceptibility of circulating influenza virus strains to Oseltamivir has been shown to be highly<br />variable. Therefore, prescribers should take into account the most recent information available on<br />Oseltamivir susceptibility patterns of the currently circulating viruses when deciding whether to&nbsp;use Oselta .<br />Severe concomitant condition<br />No information is available regarding the safety and efficacy of Oseltamivir in patients with any<br />medical condition sufficiently severe or unstable to be considered at imminent risk of requiring<br />hospitalisation.<br />Immunocompromised patients<br />The efficacy of Oseltamivir in either treatment or prophylaxis of influenza in<br />immunocompromised patients has not been firmly established.<br />Cardiac / respiratory disease<br />Efficacy of Oseltamivir in the treatment of subjects with chronic cardiac disease and/or respiratory<br />disease has not been established. No difference in the incidence of complications was observed<br />between the treatment and placebo groups in this population.<br />Paediatric population<br />No data allowing a dose recommendation for premature children (&lt; 37 weeks post-menstrual<br />age*) are currently available.<br />* Time between first day of last normal menstrual period and day of assessment, gestational age<br />plus post-natal age.<br />Severe renal impairment<br />Dose adjustment is recommended for both treatment and prevention in adolescents (13 to 17 years&nbsp;of age) and adults with severe renal impairment. There is insufficient clinical data available in<br />infants and children (1 year of age or older) with renal impairment to be able to make any dosing<br />recommendation.<br />Neuropsychiatric events<br />Neuropsychiatric events have been reported during administration of Oselta in patients with<br />influenza, especially in children and adolescents. These events are also experienced by patients<br />with influenza without Oseltamivir administration. Patients should be closely monitored for<br />behavioral changes, and the benefits and risks of continuing treatment should be carefully<br />evaluated for each patient.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacokinetic properties of Oseltamivir, such as low protein binding and metabolism<br />independent of the CYP450 and glucuronidase systems (see section 5.2), suggest that clinically<br />significant drug interactions via these mechanisms are unlikely.<br />Probenecid<br />No dose adjustment is required when co-administering with probenecid in patients with normal<br />renal function. Co-administration of probenecid, a potent inhibitor of the anionic pathway of renal<br />tubular secretion, results in an approximate 2-fold increase in exposure to the active metabolite of<br />Oseltamivir.<br />Amoxicillin<br />Oseltamivir has no kinetic interaction with amoxicillin, which is eliminated via the same pathway,<br />suggesting that Oseltamivir interaction with this pathway is weak.</p><p>Renal elimination<br />Clinically important drug interactions involving competition for renal tubular secretion are<br />unlikely, due to the known safety margin for most of these substances, the elimination<br />characteristics of the active metabolite (glomerular filtration and anionic tubular secretion) and the<br />excretion capacity of these pathways. However, care should be taken when prescribing<br />Oseltamivir in subjects when taking co-excreted agents with a narrow therapeutic margin (e.g.<br />chlorpropamide, methotrexate, phenylbutazone).<br />Additional information<br />No pharmacokinetic interactions between Oseltamivir or its major metabolite have been observed<br />when co-administering Oseltamivir with paracetamol, acetylsalicylic acid, cimetidine, antacids<br />(magnesium and aluminium hydroxides and calcium carbonates), rimantadine or warfarin (in<br />subjects stable on warfarin and without influenza).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />While no controlled clinical studies have been conducted on the use of Oseltamivir in pregnant<br />women, there is limited data available from post-marketing and retrospective observational<br />surveillance reports. These data in conjunction with animal studies do not indicate direct or<br />indirect harmful effects with respect to pregnancy, embryonal/foetal or postnatal development.<br />Pregnant women may receive Oselta, after considering the available safety information, the<br />pathogenicity of the circulating influenza virus strain and the underlying condition of the pregnant<br />woman.</p><p>Breastfeeding<br />In lactating rats, Oseltamivir and the active metabolite are excreted in milk. Very limited<br />information is available on children breast-fed by mothers taking Oseltamivir and on excretion of<br />Oseltamivir in breast milk. Limited data demonstrated that Oseltamivir and the active metabolite<br />were detected in breast milk, however the levels were low, which would result in a subtherapeutic<br />dose to the infant. Considering this information, the pathogenicity of the circulating influenza<br />virus strain and the underlying condition of the breastfeeding woman, administration of<br />Oseltamivir may be considered, where there are clear potential benefits to breastfeeding mothers.<br />Fertility<br />Based on preclinical data, there is no evidence that Oselta has an effect on male or female<br />fertility.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Oselta has no influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />The overall safety profile of Oselta is based on data from 6049 adult/adolescent and 1473<br />paediatric patients treated with Oselta or placebo for influenza, and on data from 3990<br />adult/adolescent and 253 paediatric patients receiving Oselta or placebo/no treatment for the<br />prophylaxis of influenza in clinical trials. In addition, 475 immunocompromised patients<br />(including 18 children, of these 10 Oselta and 8 placebos) received Oselta or placebo for the<br />prophylaxis of influenza.<br />In adults/adolescents, the most commonly reported adverse reactions (ARs) were nausea and&nbsp;vomiting in the treatment studies, and nausea in the prevention studies. The majority of these ARs<br />were reported on a single occasion on either the first or second treatment day and resolved<br />spontaneously within 1-2 days. In children, the most commonly reported adverse reaction was<br />vomiting. In the majority of patients, these ARs did not lead to discontinuation of Oselta.<br />The following serious adverse reactions have been rarely reported since Oseltamivir has been<br />marketed: Anaphylactic and anaphylactoid reactions, hepatic disorders (fulminant hepatitis,<br />hepatic function disorder and jaundice), angioneurotic oedema, Stevens-Johnson syndrome and<br />toxic epidermal necrolysis, gastrointestinal bleeding and neuropsychiatric disorders.<br />(Regarding neuropsychiatric disorders, see section 4.4.)<br />Tabulated list of adverse reactions<br />The ARs listed in the tables below fall into the following categories: Very common (&ge;1/10),<br />common (&ge;1/100 to &lt; 1/10), uncommon (&ge;1/1,000 to &lt; 1/100), rare (&ge;1/10,000 to &lt; 1/1,000), and<br />very rare (&lt; 1/10,000). ARs are added to the appropriate category in the tables according to the<br />pooled analysis from clinical studies.<br />Treatment and prevention of influenza in adults and adolescents:<br />In adult/adolescent treatment and prevention studies, ARs that occurred the most frequently at the<br />recommended dose (75 mg bid for 5 days for treatment and 75 mg od for up to 6 weeks for<br />prophylaxis) are shown in Table 1.<br />The safety profile reported in subjects who received the recommended dose of Oselta for<br />prophylaxis (75 mg once daily for up to 6 weeks) was qualitatively similar to that seen in the<br />treatment studies, despite a longer duration of dosing in the prophylaxis studies.</p><p>&nbsp;</p><p>Table 1 Adverse reactions in studies investigating Oselta for treatment and prevention of<br />influenza in adults and adolescents or through post-marketing surveillance<br />System Organ<br />Class (SOC)<br />Adverse reactions according to frequency<br />Very common Common Uncommon Rare<br />Infections and<br />infestations<br />Bronchitis,<br />Herpes simplex,<br />Nasopharyngitis,<br />Upper respiratory<br />tract infections,<br />Sinusitis<br />Blood and<br />lymphatic<br />system disorders<br />Thrombocytopenia<br />Immune system<br />disorders<br />Hypersensitivity<br />reaction<br />Anaphylactic<br />reactions,<br />Anaphylactoid<br />reactions<br />Psychiatric<br />disorders<br />Agitation,<br />Abnormal<br />behaviour,<br />Anxiety,<br />Confusion,<br />Delusions,<br />Delirium,<br />Hallucination,<br />Nightmares, Selfinjury<br />Nervous system<br />disorders<br />Headache Insomnia Altered level of<br />consciousness,<br />Convulsion<br />Eye disorders Visual disturbance&nbsp;</p><p>Cardiac<br />disorders<br />Cardiac<br />arrhythmia<br />Respiratory,<br />thoracic and<br />mediastinal<br />disorders<br />Cough, Sore<br />throat,<br />Rhinorrhea<br />Gastrointestinal<br />disorders<br />Nausea Vomiting<br />Abdominal pain<br />(incl. upper<br />abdominal pain),<br />Dyspepsia<br />Gastrointestinal<br />bleedings,<br />Haemorrhagic<br />colitis<br />Hepatobiliary<br />disorders<br />Elevated liver<br />enzymes<br />Fulminant<br />hepatitis, Hepatic<br />failure, Hepatitis<br />Skin and<br />subcutaneous<br />tissue disorders<br />Eczema,<br />Dermatitis, Rash,<br />Urticaria<br />Angioneurotic<br />oedema, Erythema<br />multiforme,<br />Stevens-Johnson<br />syndrome, Toxic<br />epidermal<br />necrolysis<br />General<br />disorders and<br />administration<br />site conditions<br />Pain<br />Dizziness (incl.<br />vertigo), Fatigue,<br />Pyrexia, Pain in<br />limb</p><p>Treatment and prevention of influenza in children:<br />A total of 1473 children (including otherwise healthy children aged 1-12 years old and asthmatic<br />children aged 6-12 years old) participated in clinical studies of Oseltamivir given for the treatment<br />of influenza. Of those, 851 children received treatment with Oseltamivir suspension. A total of</p><p>158 children received the recommended dose of Oselta once daily in a post-exposure prophylaxis<br />study in households (n = 99), a 6-week paediatric seasonal prophylaxis study (n = 49) and a 12-<br />week paediatric seasonal prophylaxis study in immunocompromised subjects (n = 10).<br />Table 2 shows the most frequently reported ARs from paediatric clinical trials.<br />Table 2 Adverse reactions in studies investigating Oselta for treatment and prevention of<br />influenza in children (age/weight-based dosing [30 mg to 75 mg o.d.])<br />System Organ<br />Class (SOC)<br />Adverse reactions according to frequency<br />Very common Common Uncommon Rare<br />Infections and<br />infestations<br />Otitis media,<br />Nervous system<br />disorders<br />Headache<br />Eye disorders: Conjunctivitis<br />(including red<br />eyes, eye<br />discharge and eye<br />pain)<br />Ear and<br />labyrinth<br />disorders:<br />Earache Tympanic<br />membrane<br />disorder<br />Respiratory,<br />thoracic and<br />mediastinal<br />disorders<br />Cough, Nasal<br />congestion<br />Rhinorrhoea<br />Gastrointestinal<br />disorders<br />Vomiting Abdominal pain<br />(incl. upper<br />abdominal pain),<br />Dyspepsia,<br />Nausea</p><p>Skin and<br />subcutaneous<br />tissue disorders<br />Dermatitis<br />(including<br />allergic and<br />atopic dermatitis)</p><p>Description of selected adverse reactions<br />Psychiatric disorders and nervous system disorders<br />Influenza can be associated with a variety of neurologic and behavioural symptoms which can<br />include events such as hallucinations, delirium, and abnormal behaviour, in some cases resulting<br />in fatal outcomes. These events may occur in the setting of encephalitis or encephalopathy but can<br />occur without obvious severe disease.<br />In patients with influenza who were receiving Oselta , there have been postmarketing reports of<br />convulsions and delirium (including symptoms such as altered level of consciousness, confusion,<br />abnormal behaviour, delusions, hallucinations, agitation, anxiety, nightmares), in a very few cases<br />resulting in self-injury or fatal outcomes. These events were reported primarily among paediatric<br />and adolescent patients and often had an abrupt onset and rapid resolution. The contribution of<br />Oselta to those events is unknown. Such neuropsychiatric events have also been reported in<br />patients with influenza who were not taking Oselta .<br />Hepato-biliary disorders<br />Hepato-biliary system disorders, including hepatitis and elevated liver enzymes in patients with<br />influenza-like illness. These cases include fatal fulminant hepatitis/hepatic failure.<br />Other special populations<br />Paediatric population (infants less than one year of age)</p><p>Safety information available on Oseltamivir administered for treatment of influenza in infants less<br />than one year of age from prospective and retrospective observational studies (comprising<br />together more than 2,400 infants of that age class), epidemiological databases research and<br />postmarketing reports suggest that the safety profile in infants less than one year of age is similar<br />to the established safety profile of children aged one year and older.<br />Elderly patients and patients with chronic cardiac and/or respiratory disease<br />The population included in the influenza treatment studies is comprised of otherwise healthy<br />adults/adolescents and patients &ldquo;at risk&rdquo; (patients at higher risk of developing complications<br />associated with influenza, e.g. elderly patients and patients with chronic cardiac or respiratory<br />disease). In general, the safety profile in the patients &ldquo;at risk&rdquo; was qualitatively similar to that in<br />otherwise healthy adults/adolescents.<br />Immunocompromised patients<br />In a 12-week prophylaxis study in 475 immunocompromised patients, including 18 children 1 to<br />12 years of age and older, the safety profile in the 238 patients who received Oseltamivir was<br />consistent with that previously observed in Oselta prophylaxis clinical studies.<br />Children with pre-existing bronchial asthma<br />In general, the adverse reaction profile in children with pre-existing bronchial asthma was<br />qualitatively similar to that of otherwise healthy children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reports of overdoses with Oselta have been received from clinical trials and during postmarketing<br />experience. In the majority of cases reporting overdose, no adverse events were&nbsp;reported.<br />Adverse events reported following overdose were similar in nature and distribution to those<br />observed with therapeutic doses of Oselta, described in section 4.8 Undesirable effects.<br />No specific antidote is known.<br />Paediatric population<br />Overdose has been reported more frequently for children than adults and adolescents. Caution<br />should be exercised when preparing Oselta oral suspension and when administering Oselta<br />products to children.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antivirals for systemic use, neuraminidase inhibitors ATC code:<br />J05AH02<br />Oseltamivir phosphate is a pro-drug of the active metabolite (Oseltamivir carboxylate). The active<br />metabolite is a selective inhibitor of influenza virus neuraminidase enzymes, which are<br />glycoproteins found on the virion surface. Viral neuraminidase enzyme activity is important both<br />for viral entry into uninfected cells and for the release of recently formed virus particles from<br />infected cells, and for the further spread of infectious virus in the body.<br />Oseltamivir carboxylate inhibits influenza A and B neuraminidases in vitro. Oseltamivir<br />phosphate inhibits influenza virus infection and replication in vitro. Oseltamivir given orally<br />inhibits influenza A and B virus replication and pathogenicity in vivo in animal models of<br />influenza infection at antiviral exposures similar to that achieved in man with 75 mg twice daily.</p><p>Antiviral activity of Oseltamivir was supported for influenza A and B by experimental challenge<br />studies in healthy volunteers.<br />Neuraminidase enzyme IC50 values for Oseltamivir for clinically isolated influenza A ranged<br />from 0.1 nM to 1.3 nM, and for influenza B was 2.6 nM. Higher IC50 values for influenza B, up<br />to a median of 8.5 nM, have been observed in published studies.<br />Clinical studies<br />Treatment of influenza infection<br />Oseltamivir is effective only against illnesses caused by influenza virus. Statistical analyses are<br />therefore presented only for influenza-infected subjects. In the pooled treatment study population,<br />which included both influenza-positive and -negative subjects (ITT), primary efficacy was<br />reduced proportionally to the number of influenza-negative individuals. In the overall treatment<br />population, influenza infection was confirmed in 67 % (range 46 % to 74 %) of the recruited<br />patients. Of the elderly subjects, 64 % were influenza-positive and of those with chronic cardiac<br />and/or respiratory disease 62 % were influenza-positive. In all phase III treatment studies, patients<br />were recruited only during the period in which influenza was circulating in the local community.<br />Adults and adolescents 13 years of age and older: Patients were eligible if they reported within 36<br />hours of onset of symptoms, had fever &ge; 37.8 &deg;C, accompanied by at least one respiratory<br />symptom (cough, nasal symptoms or sore throat) and at least one systemic symptom (myalgia,<br />chills/sweats, malaise, fatigue or headache). In a pooled analysis of all influenza-positive adults<br />and adolescents (N = 2,413) enrolled into treatment studies, Oseltamivir 75 mg twice daily for 5<br />days reduced the median duration of influenza illness by approximately one day from 5.2 days (95<br />% CI 4.9 &ndash; 5.5 days) in the placebo group to 4.2 days (95 % CI 4.0 &ndash; 4.4 days; p &le; 0.0001).<br />The proportion of subjects who developed specified lower respiratory tract complications (mainly&nbsp;bronchitis) treated with antibiotics was reduced from 12.7 % (135/1,063) in the placebo group to<br />8.6 % (116/1,350) in the Oseltamivir treated population (p = 0.0012).<br />Treatment of influenza in high risk populations: The median duration of influenza illness in<br />elderly subjects (&ge; 65 years) and in subjects with chronic cardiac and/or respiratory disease<br />receiving Oseltamivir 75 mg twice daily for 5 days was not reduced significantly. The total<br />duration of fever was reduced by one day in the groups treated with oseltamivir. In the influenzapositive<br />elderly, Oseltamivir significantly reduced the incidence of specified lower respiratory<br />tract complications (mainly bronchitis) treated with antibiotics from 19 % (52/268) in the placebo<br />group to 12 % (29/250) in the Oseltamivir treated population (p = 0.0156).<br />In influenza-positive patients with chronic cardiac and/or respiratory disease, the combined<br />incidence of lower respiratory tract complications (mainly bronchitis) treated with antibiotics was<br />17 % (22/133) in the placebo group and 14 % (16/118) in the Oseltamivir treated population (p =<br />0.5976).<br />Treatment of influenza in children: In a study of otherwise healthy children (65 % influenzapositive)<br />aged 1 to 12 years (mean age 5.3 years) who had fever (&ge; 37.8 &deg;C) plus either cough or<br />coryza, 67 % of influenza-positive patients were infected with influenza A and 33 % with<br />influenza B. Oseltamivir treatment, started within 48 hours of onset of symptoms, significantly<br />reduced the time to freedom from illness (defined as the simultaneous return to normal health and<br />activity and alleviation of fever, cough and coryza) by 1.5 days (95 % CI 0.6 &ndash; 2.2 days; p &lt;<br />0.0001) compared to placebo. Oseltamivir reduced the incidence of acute otitis media from 26.5<br />% (53/200) in the placebo group to 16 % (29/183) in the Oseltamivir treated children (p = 0.013).<br />A second study was completed in 334 asthmatic children aged 6 to 12 years old of which 53.6 %<br />were influenza-positive. In the Oseltamivir treated group, the median duration of illness was not<br />reduced significantly. By day 6 (the last day of treatment) FEV1 had increased by 10.8 % in the<br />Oseltamivir treated group compared to 4.7 % on placebo (p = 0.0148) in this population.</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with<br />Oselta in one or more subsets of the paediatric population in influenza. See section 4.2 for<br />information on paediatric use.<br />Treatment of influenza B infection: Overall, 15 % of the influenza-positive population were<br />infected by influenza B, proportions ranging from 1 to 33 % in individual studies. The median<br />duration of illness in influenza B infected subjects did not differ significantly between the<br />treatment groups in individual studies. Data from 504 influenza B infected subjects were pooled<br />across all studies for analysis. Oseltamivir reduced the time to alleviation of all symptoms by 0.7<br />days (95 % CI 0.1 &ndash; 1.6 days; p = 0.022) and the duration of fever (&ge; 37.8 &deg;C), cough and coryza<br />by one day (95 % CI 0.4 &ndash; 1.7 days; p &lt; 0.001) compared to placebo.<br />Prevention of influenza<br />The efficacy of Oseltamivir in preventing naturally occurring influenza illness has been<br />demonstrated in a post-exposure prevention study in households and two seasonal prevention<br />studies. The primary efficacy parameter for all of these studies was the incidence of laboratoryconfirmed<br />influenza. The virulence of influenza epidemics is not predictable and varies within a<br />region and from season to season, therefore the number needed to treat (NNT) in order to prevent<br />one case of influenza illness varies.<br />Post-exposure prevention: In a study in contacts (12.6 % vaccinated against influenza) of an index<br />case of influenza, Oseltamivir 75 mg once daily was started within 2 days of onset of symptoms in<br />the index case and continued for seven days. Influenza was confirmed in 163 out of 377 index<br />cases. Oseltamivir significantly reduced the incidence of clinical influenza illness occurring in the<br />contacts of confirmed influenza cases from 24/200 (12 %) in the placebo group to 2/205 (1 %) in<br />the Oseltamivir group (92 % reduction [95 % CI 6 &ndash; 16; p &le; 0.0001]). The number needed to treat<br />(NNT) in contacts of true influenza cases was 10 (95 % CI 9 &ndash; 12) and was 16 (95 % CI 15 &ndash; 19)</p><p>in the whole population (ITT) regardless of infection status in the index case.<br />The efficacy of Oseltamivir in preventing naturally occurring influenza illness has been<br />demonstrated in a post-exposure prevention study in households that included adults, adolescents,<br />and children aged 1 to 12 years, both as index cases and as family contacts. The primary efficacy<br />parameter for this study was the incidence of laboratory-confirmed clinical influenza in the<br />households. Oseltamivir prophylaxis lasted for 10 days. In the total population, there was a<br />reduction in the incidence of laboratory-confirmed clinical influenza in households from 20 %<br />(27/136) in the group not receiving prevention to 7 % (10/135) in the group receiving prevention<br />(62.7 % reduction [95 % CI 26.0 &ndash; 81.2; p = 0.0042]). In households of influenza-infected index<br />cases, there was a reduction in the incidence of influenza from 26 % (23/89) in the group not<br />receiving prevention to 11 % (9/84) in the group receiving prevention (58.5 % reduction [95 % CI<br />15.6 &ndash; 79.6; p = 0.0114]).<br />According to subgroup analysis in children at 1 to 12 years of age, the incidence of laboratoryconfirmed<br />clinical influenza among children was significantly reduced from 19 % (21/111) in the<br />group not receiving prevention to 7 % (7/104) in the group receiving prevention (64.4 % reduction<br />[95 % CI 15.8 &ndash; 85.0; p = 0.0188]). Among children who were not already shedding virus at<br />baseline, the incidence of laboratory-confirmed clinical influenza was reduced from 21 % (15/70)<br />in the group not receiving prevention to 4 % (2/47) in the group receiving prevention (80.1 %<br />reduction [95 % CI 22.0 &ndash; 94.9; p = 0.0206]). The NNT for the total paediatric population was 9<br />(95 % CI 7 &ndash; 24) and 8 (95 % CI 6, upper limit not estimable) in the whole population (ITT) and<br />in paediatric contacts of infected index cases (ITTII), respectively.<br />Prevention during an influenza epidemic in the community: In a pooled analysis of two other<br />studies conducted in unvaccinated otherwise healthy adults, Oseltamivir 75 mg once daily given<br />for 6 weeks significantly reduced the incidence of clinical influenza illness from 25/519 (4.8 %) in<br />the placebo group to 6/520 (1.2 %) in the Oseltamivir group (76 % reduction [95 % CI 1.6 &ndash; 5.7; p&nbsp;</p><p>= 0.0006]) during a community outbreak of influenza. The NNT in this study was 28 (95 % CI 24<br />&ndash; 50).<br />A study in elderly residents of nursing homes, where 80 % of participants received vaccine in the<br />season of the study, Oseltamivir 75 mg once daily given for 6 weeks significantly reduced the<br />incidence of clinical influenza illness from 12/272 (4.4 %) in the placebo group to 1/276 (0.4 %)<br />in the Oseltamivir group (92 % reduction [95 % CI 1.5 &ndash; 6.6; p = 0.0015]). The NNT in this study<br />was 25 (95 % CI 23 &ndash; 62).<br />Prophylaxis of influenza in immunocompromised patients: A double-blind, placebo-controlled,<br />randomised study was conducted for seasonal prophylaxis of influenza in 475<br />immunocompromised patients (388 patients with solid organ transplantation [195 placebo; 193<br />oseltamivir], 87 patients with haemopoetic stem cell transplantation [43 placebo; 44 oseltamivir],<br />no patient with other immunosuppressant conditions), including 18 children 1 to 12 years of age.<br />The primary endpoint in this study was the incidence of laboratory-confirmed clinical influenza as<br />determined by viral culture and/or a four-fold rise in HAI antibodies. The incidence of<br />laboratory-confirmed clinical influenza was 2.9 % (7/238) in the placebo group and 2.1 % (5/237)<br />in the Oseltamivir group (95 % CI -2.3 % &ndash; 4.1 %; p = 0.772).<br />Specific studies have not been conducted to assess the reduction in the risk of complications.<br />Oseltamivir resistance<br />Clinical studies: The risk of emergence of influenza viruses with reduced susceptibility or frank<br />resistance to Oseltamivir has been examined during Roche-sponsored clinical studies. All patients<br />who were found to carry oseltamivir-resistant virus did so transiently, cleared the virus normally<br />and showed no clinical deterioration.</p><p>Patient Population Patients with Resistance Mutations (%)<br />Phenotyping* Geno- and Phenotyping*<br />Adults and adolescents 4/1,245 (0.32 %) 5/1,245 (0.4 %)<br />Children (1-12 years) 19/464 (4.1 %) 25/464 (5.4 %)<br />* Full genotyping was not performed in all studies.<br />There has been no evidence for emergence of drug resistance associated with the use of Oselta in<br />clinical studies conducted to date in post-exposure (7 days), post-exposure within household<br />groups (10 days) and seasonal (42 days) prevention of influenza in immunocompetent patients.<br />There was no resistance observed during a 12-week prophylaxis study in immunocompromised<br />patients.<br />Clinical and surveillance data: Natural mutations associated with reduced susceptibility to<br />Oseltamivir in vitro have been detected in influenza A and B viruses isolated from patients<br />without exposure to oseltamivir. Resistant strains selected during Oseltamivir treatment have been<br />isolated from both immunocompetent and immunocompromised patients. Immunocompromised<br />patients and young children are at a higher risk of developing oseltamivir-resistant virus during<br />treatment.<br />Oseltamivir-resistant viruses isolated from oseltamivir-treated patients and oseltamivir-resistant<br />laboratory strains of influenza viruses have been found to contain mutations in N1 and N2<br />neuraminidases. Resistance mutations tend to be viral sub-type specific. Since 2007 resistance<br />associated H275Y mutation in seasonal H1N1 strains has become widespread. The susceptibility<br />to Oseltamivir and the prevalence of such viruses appear to vary seasonally and geographically. In<br />2008, H275Y was found in &gt; 99 % of circulating H1N1 influenza isolates in Europe. The 2009<br />H1N1 influenza (&ldquo;swine flu&rdquo;) was almost uniformly susceptible to Oseltamivir, with only<br />sporadic reports of resistance in connection with both therapeutic and prophylactic regimens.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General Information<br />Absorption<br />Oseltamivir is readily absorbed from the gastrointestinal tract after oral administration of<br />Oseltamivir phosphate (pro-drug) and is extensively converted by predominantly hepatic esterases<br />to the active metabolite (Oseltamivir carboxylate). At least 75 % of an oral dose reaches the<br />systemic circulation as the active metabolite. Exposure to the pro-drug is less than 5 % relative to<br />the active metabolite. Plasma concentrations of both pro-drug and active metabolite are proportional<br />to dose and are unaffected by co-administration with food.<br />Distribution<br />The mean volume of distribution at steady state of the Oseltamivir carboxylate is approximately 23<br />litres in humans, a volume equivalent to extracellular body fluid. Since neuraminidase activity is<br />extracellular, Oseltamivir carboxylate distributes to all sites of influenza virus spread.<br />The binding of the Oseltamivir carboxylate to human plasma protein is negligible (approximately 3<br />%).<br />Biotransformation<br />Oseltamivir is extensively converted to Oseltamivir carboxylate by esterases located predominantly<br />in the liver. In vitro studies demonstrated that neither Oseltamivir nor the active metabolite is a<br />substrate for, or an inhibitor of, the major cytochrome P450 isoforms. No phase 2 conjugates of<br />either compound have been identified in vivo.<br />Elimination&nbsp;Absorbed Oseltamivir is primarily (&gt; 90 %) eliminated by conversion to Oseltamivir carboxylate. It<br />is not further metabolised and is eliminated in the urine. Peak plasma concentrations of Oseltamivir<br />carboxylate decline with a half-life of 6 to 10 hours in most subjects. The active metabolite is<br />eliminated entirely by renal excretion. Renal clearance (18.8 l/h) exceeds glomerular filtration rate<br />(7.5 l/h) indicating that tubular secretion occurs in addition to glomerular filtration. Less than 20 %<br />of an oral radiolabelled dose is eliminated in faeces.<br />Special populations<br />Children<br />Infants less than 1 year of age: Limited pharmacokinetic and safety data are available for infants<br />less than 1 year of age. Pharmacokinetic modeling was undertaken using these data in addition to<br />data from studies in adults and infants and children 1 year of age or older. The results demonstrate<br />that doses of 3 mg /kg twice daily for infants aged 3 to 12 months and 2.5 mg /kg twice daily for<br />infants aged between 1 and 3 months provide exposures similar to those shown to be clinically<br />efficacious in adults and infants and children 1 year of age or older (see sections 4.1 and 4.2). There<br />are currently no data available in infants less than 1 month of age using Oselta .<br />Infants and children 1 year of age or older: The pharmacokinetics of Oseltamivir has been<br />evaluated in single-dose pharmacokinetic studies in infants, children and adolescents 1 to 16 years<br />of age. Multiple-dose pharmacokinetics were studied in a small number of children enrolled in a<br />clinical efficacy study. Younger children cleared both the pro-drug and its active metabolite faster<br />than adults, resulting in a lower exposure for a given mg/kg dose. Doses of 2 mg/kg give<br />Oseltamivir carboxylate exposures comparable to those achieved in adults receiving a single 75 mg<br />dose (approximately 1 mg/kg). The pharmacokinetics of Oseltamivir in children and adolescents 12<br />years of age or older are similar to those in adults.</p><p>Elderly<br />Exposure to the active metabolite at steady state was 25 to 35 % higher in elderly (age 65 to 78<br />years) compared to adults less than 65 years of age given comparable doses of oseltamivir. Halflives<br />observed in the elderly were similar to those seen in young adults. On the basis of drug<br />exposure and tolerability, dosage adjustments are not required for elderly patients unless there is<br />evidence of moderate or severe renal impairment (creatinine clearance below 60 ml /min).<br />Renal impairment<br />Administration of 100 mg Oseltamivir phosphate twice daily for 5 days to patients with various<br />degrees of renal impairment showed that exposure to Oseltamivir carboxylate is inversely<br />proportional to declining renal function. For dosing, see section 4.2.<br />Hepatic impairment<br />In vitro studies have concluded that exposure to Oseltamivir is not expected to be increased<br />significantly nor is exposure to the active metabolite expected to be significantly decreased in<br />patients with hepatic impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies of safety<br />pharmacology, repeated-dose toxicity and genotoxicity. Results of the conventional rodent<br />carcinogenicity studies showed a trend towards a dose-dependent increase in the incidence of some<br />tumours that are typical for the rodent strains used. Considering the margins of exposure in relation<br />to the expected exposure in the human use, these findings do not change the benefit-risk of Oselta in<br />its adopted therapeutic indications.</p><p>Teratology studies have been conducted in rats and rabbits at doses of up to 1,500 mg/kg/day and<br />500 mg/kg/day, respectively. No effects on foetal development were observed. A rat fertility study<br />up to a dose of 1,500 mg/kg/day demonstrated no adverse reactions on either sex. In pre- and postnatal<br />rat studies, prolonged parturition was noted at 1,500 mg/kg/day: the safety margin between<br />human exposure and the highest no-effect dose (500 mg/kg/day) in rats is 480-fold for Oseltamivir<br />and 44-fold for the active metabolite, respectively. Foetal exposure in the rats and rabbits was<br />approximately 15 to 20 % of that of the mother.<br />In lactating rats, Oseltamivir and the active metabolite are excreted in the milk. Limited data<br />indicate that Oseltamivir and the active metabolite are excreted in human milk. Extrapolation of the<br />animal data provides estimates of 0.01 mg/day and 0.3 mg/day for the respective compounds.<br />A potential for skin sensitisation to Oseltamivir was observed in a &quot;maximisation&quot; test in guinea<br />pigs. Approximately 50 % of the animals treated with the unformulated active substance showed<br />erythema after challenging the induced animals. Reversible irritancy of rabbits&#39; eyes was detected.<br />Whereas very high oral single doses of Oseltamivir phosphate salt, up to the highest dose tested<br />(1,310 mg/kg), had no adverse reactions in adult rats, such doses resulted in toxicity in juvenile 7-<br />day-old rat pups, including death. These reactions were seen at doses of 657 mg/kg and higher. At<br />500 mg/kg, no adverse reactions were seen, including upon chronic treatment (500 mg/kg/day<br />administered from 7 to 21 days post partum).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Croscarmellose sodium<br />Pregelatinised starch<br />Ludipress<br />Povidone K30</p><p>Talc<br />Colloidal silicon dioxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30 &deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Immediate Container:<br />Al-Foil 249mm : Plain Aluminum foil.<br />PVC/ACLAR Film : Clear &amp; transparent<br />Secondary packaging (outer)<br />Carton : Colored printed carton, Dimensions 89x 68 x 16 mm<br />Insert/Leaflet : PIL 150 x 480 mm</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.<br />Extemporaneous formulation<br />When Oselta powder for oral suspension is not available<br />When commercially manufactured Oselta powder for oral suspension is not available, patients who&nbsp;are unable to swallow capsules may receive appropriate doses of Oselta prepared in a pharmacy or<br />prepared at home.<br />For infants less than 1 year of age, the pharmacy preparation should be preferred to home<br />preparation. Detailed information on the home preparation can be found in the package leaflet of<br />Oselta capsules under &ldquo;Making Oselta suspension at home&rdquo;.<br />Syringes of appropriate volume and grading should be provided for administering the pharmacy<br />compounded suspension as well as for the procedures involved in the home preparation. In both<br />cases, the correct volumes should preferably be marked on the syringes.<br />Pharmacy compounding<br />Pharmacy compounded 6 mg/ml suspension prepared from capsules<br />Adults, adolescents and infants and children 1 year of age or older who are unable to swallow<br />intact capsules<br />This procedure describes the preparation of a 6 mg/ml suspension that will provide one patient with<br />enough medicine for a 5-day course of treatment or a 10-day course of prophylaxis.<br />The pharmacist may compound a 6 mg/ml suspension from Oselta 30 mg, 45 mg or 75 mg capsules<br />using water containing 0.05 % w/v sodium benzoate added as a preservative.<br />First, calculate the total volume needed to be compounded and dispensed to provide a 5-day course<br />of treatment or a 10-day course of prophylaxis for the patient. The total volume required is<br />determined by the weight of the patient according to the recommendation in the table below. To<br />allow for accurate volume withdrawal of up to 10 doses (2 withdrawals per daily treatment dose for<br />5 days), the column indicating measurement loss is to be considered for compounding.</p><p>Volume of pharmacy compounded 6 mg/ml suspension prepared based upon the patient&#39;s<br />weight<br />Body weight<br />(kg)<br />Total volume to compound per<br />patient weight<br />(ml)<br />Measurement loss not considered<br />Total volume to compound per<br />patient weight<br />(ml)<br />Measurement loss considered<br />10 kg to 15 kg 50 ml 60 ml or 75 ml*<br />&gt; 15 kg to 23 kg 75 ml 90 ml or 100 ml*<br />&gt; 23 kg to 40 kg 100 ml 125 ml<br />&gt; 40 kg 125 ml 137.5 ml (or 150 ml)*<br />* Depending on the capsule strength used.<br />Second, determine the number of capsules and the amount of vehicle (water containing 0.05 % w/v<br />sodium benzoate added as a preservative) that is needed to prepare the total volume (calculated<br />from the table above) of pharmacy compounded 6 mg/ml suspension as shown in the table below:<br />Number of capsules and amount of vehicle needed to prepare the total volume of a pharmacy<br />compounded 6 mg/ml suspension<br />Total volume of<br />compounded<br />suspension to be<br />prepared<br />Required number of Oselta capsules<br />(mg of Oseltamivir)<br />Required volume<br />of vehicle<br />75 mg 45 mg 30 mg<br />50 ml 4 capsules<br />(300 mg)<br />Please use<br />alternative<br />capsule strength*<br />10 capsules<br />(300 mg)<br />49.5 ml<br />60 ml Please use<br />alternative<br />8 capsules 12 capsules 59.5 ml</p><p>capsule strength*<br />(360 mg) (360 mg)<br />75 ml 6 capsules<br />(450 mg)<br />10 capsules<br />(450 mg)<br />15 capsules<br />(450 mg)<br />74 ml<br />90 ml Please use<br />alternative<br />capsule strength*<br />12 capsules<br />(540 mg)<br />18 capsules<br />(540 mg)<br />89 ml<br />100 ml 8 capsules<br />(600 mg)<br />Please use<br />alternative<br />capsule strength*<br />20 capsules<br />(600 mg)<br />98.5 ml<br />125 ml 10 capsules<br />(750 mg)<br />Please use<br />alternative<br />capsule strength*<br />25 capsules<br />(750 mg)<br />123.5 ml<br />137.5 ml 11 capsules<br />(825 mg)<br />Please use<br />alternative<br />capsule strength*<br />Please use<br />alternative<br />capsule strength*<br />136 ml</p><p>* There is no combination of this capsule strength that can be used to achieve the target<br />concentration; therefore, please use an alternative capsule strength.<br />Third, follow the procedure below for compounding the 6 mg/ml suspension from Oselta capsules:<br />1. In a glass beaker of suitable size place the stated amount of water containing 0.05 % w/v sodium<br />benzoate added as a preservative.<br />2. Open the stated amount of Oselta capsules and transfer the content of each capsule directly to the<br />preserved water in the glass beaker.<br />3. With a suitable stirring device, stir for 2 minutes.<br />(Note: The drug substance, Oseltamivir phosphate, readily dissolves in water. The suspension is</p><p>caused by some of the excipients of Oselta capsules, which are insoluble.)<br />4. Transfer the suspension to an amber glass or amber polyethyleneterephthalate (PET) bottle. A<br />funnel may be used to eliminate any spillage.<br />5. Close the bottle using a child-resistant cap.<br />6. Put an ancillary label on the bottle indicating &ldquo;Shake Gently Before Use&rdquo;.<br />(Note: This compounded suspension should be gently shaken prior to administration to minimize<br />the tendency for air entrapment.)<br />7. Instruct the parent or caregiver that any remaining material following completion of therapy must<br />be discarded. It is recommended that this information be provided by either affixing an ancillary<br />label to the bottle or adding a statement to the pharmacy label instructions.<br />8. Place an appropriate expiration date label according to storage condition (see section 6.3).<br />Place a pharmacy label on the bottle that includes the patient&#39;s name, dosing instructions, use by<br />date, name of medicinal product and any other required information to be in compliance with local<br />pharmacy regulations. Refer to the table below for the proper dosing instructions.<br />Dosing chart for pharmacy-compounded 6 mg/ml suspension prepared from Oselta capsules<br />for infants and children 1 year of age or older<br />Body weight<br />(kg)<br />Dose<br />(mg)<br />Volume per dose<br />6 mg/ml<br />Treatment dose<br />(for 5 days)<br />Prophylaxis dose<br />(for 10 days)<br />10 kg to 15 kg 30 mg 5 ml 5 ml twice daily 5 ml once daily<br />&gt; 15 kg to 23 kg 45 mg 7.5 ml 7.5 ml twice daily 7.5 ml once daily&nbsp;</p><p>&gt; 23 kg to 40 kg 60 mg 10 ml 10 ml twice daily 10 ml once daily<br />&gt; 40 kg 75 mg 12.5 ml 12.5 ml twice<br />daily<br />12.5 ml once<br />daily<br />Dispense the pharmacy compounded suspension with a graduated oral syringe for measuring small<br />amounts of suspension. If possible, mark or highlight the graduation corresponding to the<br />appropriate dose (according to the dosing table above) on the oral syringe for each patient.<br />The appropriate dose must be mixed by the caregiver with an equal quantity of sweet liquid food,<br />such as sugar water, chocolate syrup, cherry syrup, dessert toppings (like caramel or fudge sauce) to<br />mask the bitter taste.<br />Infants less than 1 year of age<br />This procedure describes the preparation of a 6 mg/ml suspension that will provide one patient with<br />enough medication for a 5-day course of treatment or a 10-day course of prophylaxis.<br />The pharmacist may compound a 6 mg/ml suspension from Oselta 30 mg, 45 mg or 75 mg capsules<br />using water containing 0.05 % w/v sodium benzoate added as a preservative.<br />First, calculate the total volume needed to be compounded and dispensed for each patient. The total<br />volume required is determined by the weight of the patient according to the recommendation in the<br />table below. To allow for accurate volume withdrawal of up to 10 doses (2 withdrawals per daily<br />treatment dose for 5 days), the column indicating measurement loss is to be considered for<br />compounding.<br />Volume of pharmacy compounded 6 mg/ml suspension prepared based upon the patient&#39;s<br />weight<br />Body weight Total volume to compound per Total volume to compound per</p><p>(kg)<br />patient weight<br />(ml)<br />Measurement loss not considered<br />patient weight<br />(ml)<br />Measurement loss considered<br />&le; 7 kg up to 40 ml 50 ml<br />&gt; 7 kg to 10 kg 50 ml 60 ml or 75 ml*<br />* Depending on the capsule strength used.<br />Second, determine the number of capsules and the amount of vehicle (water containing 0.05 % w/v<br />sodium benzoate added as a preservative) that is needed to prepare the total volume (calculated<br />from the table above) of pharmacy compounded 6 mg/ml suspension as shown in the table below:<br />Number of capsules and amount of vehicle needed to prepare the total volume of a pharmacy<br />compounded 6 mg/ml suspension<br />Total volume of<br />compounded<br />suspension to be<br />prepared<br />Required number of Oselta capsules<br />(mg of Oseltamivir)<br />Required volume<br />of vehicle<br />75 mg 45 mg 30 mg<br />30 ml Please use<br />alternative<br />capsule strength*<br />4 capsules<br />(180 mg)<br />6 capsules<br />(180 mg)<br />29.5 ml<br />50 ml 4 capsules<br />(300 mg)<br />Please use<br />alternative<br />capsule strength*<br />10 capsules<br />(300 mg)<br />49.5 ml<br />60 ml Please use<br />alternative<br />capsule strength*<br />8 capsules<br />(360 mg)<br />12 capsules<br />(360 mg)<br />59.5 ml<br />75 ml 6 capsules 10 capsules 15 capsules 74 ml</p><p>(450 mg) (450 mg) (450 mg)<br />* There is no combination of this capsule strength that can be used to achieve the target<br />concentration; therefore, please use an alternative capsule strength.<br />Third, follow the procedure below for compounding the 6 mg/ml suspension from Oselta capsules:<br />1. In a glass beaker of suitable size place the stated amount of water containing 0.05 % w/v sodium<br />benzoate added as a preservative.<br />2. Open the stated amount of Oselta capsules and transfer the content of each capsule directly to the<br />preserved water in the glass beaker.<br />3. With a suitable stirring device, stir for 2 minutes.<br />(Note: The drug substance, Oseltamivir phosphate, readily dissolves in water. The suspension is<br />caused by some of the excipients of Oselta capsules, which are insoluble.)<br />4. Transfer the suspension to an amber glass or amber polyethyleneterephthalate (PET) bottle. A<br />funnel may be used to eliminate any spillage.<br />5. Close the bottle using a child-resistant cap.<br />6. Put an ancillary label on the bottle indicating &ldquo;Shake Gently Before Use&rdquo;.<br />(Note: This compounded suspension should be gently shaken prior to administration to minimize<br />the tendency for air entrapment.)<br />7. Instruct the parent or caregiver that any remaining material following completion of therapy must<br />be discarded. It is recommended that this information be provided by either affixing an ancillary</p><p>label to the bottle or adding a statement to the pharmacy label instructions.<br />8. Place an appropriate expiration date label according to storage condition .<br />Place a pharmacy label on the bottle that includes the patient&#39;s name, dosing instructions, use by<br />date, name of medicinal product and any other required information to be in compliance with local<br />pharmacy regulations. Refer to the table below for the proper dosing instructions.<br />Dosing chart for pharmacy compounded 6 mg/ml suspension prepared from Oselta capsules<br />for infants 0 to 30 days of age (less than one month of age)<br />Body Weight<br />(rounded to<br />the nearest 0.5<br />kg)<br />Dose<br />(mg)<br />Volume per<br />dose<br />(6 mg/ml)<br />Treatment<br />Dose<br />(for 5 days)<br />Prophylaxis<br />Dose<br />(for 10 days)<br />Dispenser size<br />to use<br />(grading 0.1 ml)<br />3 kg 6 mg 1.0 ml 1.0 ml twice<br />daily<br />1.0 ml once daily 1.0 ml (or 2.0<br />ml)<br />3.5 kg 7 mg 1.2 ml 1.2 ml twice<br />daily<br />1.2 ml once daily 2.0 ml<br />4 kg 8 mg 1.3 ml 1.3 ml twice<br />daily<br />1.3 ml once daily 2.0 ml<br />4.5 kg 9 mg 1.5 ml 1.5 ml twice<br />daily<br />1.5 ml once daily 2.0 ml<br />Dosing chart for pharmacy compounded 6 mg/ml suspension prepared from Oselta capsules<br />for infants of 31 to 90 days of age (more than one month to three months of age)<br />Body Weight<br />(rounded to<br />the nearest 0.5<br />kg)<br />Dose<br />(mg)<br />Volume per<br />dose<br />(6 mg/ml)<br />Treatment<br />Dose<br />(for 5 days)<br />Prophylaxis<br />Dose<br />(for 10 days)<br />Dispenser size<br />to use<br />(grading 0.1 ml</p><p>4 kg 10 mg 1.7 ml 1.7 ml twice<br />daily<br />1.7 ml once daily 2.0 ml (or 3.0<br />ml)<br />4.5 kg 11.25 mg 1.9 ml 1.9 ml twice<br />daily<br />1.9 ml once daily 2.0 ml (or 3.0<br />ml)<br />5 kg 12.5 mg 2.1 ml 2.1 ml twice<br />daily<br />2.1 ml once daily 3.0 ml<br />5.5 kg 13.75 mg 2.3 ml 2.3 ml twice<br />daily<br />2.3 ml once daily 3.0 ml<br />6 kg 15 mg 2.5 ml 2.5 ml twice<br />daily<br />2.5 ml once daily 3.0 ml<br />6.5 kg 16.25 mg 2.7 ml 2.7 ml twice<br />daily<br />2.7 ml once daily 3.0 ml<br />Dosing chart for pharmacy compounded 6 mg/ml suspension prepared from Oselta capsules<br />for infants 91 to less than 365 days of age (more than three months to twelve months of age)<br />Body Weight<br />(rounded to<br />the nearest 0.5<br />kg)<br />Dose<br />(mg)<br />Volume per<br />dose<br />(6 mg/ml)<br />Treatment<br />Dose<br />(for 5 days)<br />Prophylaxis<br />Dose<br />(for 10 days)<br />Dispenser size<br />to use<br />(grading 0.1 ml)<br />6 kg 18 mg 3.0 ml 3.0 ml twice<br />daily<br />3.0 ml once daily 3.0 ml (or 5.0<br />ml)<br />6.5 kg 19.5 mg 3.3 ml 3.3 ml twice<br />daily<br />3.3 ml once daily 5.0 ml<br />7 kg 21 mg 3.5 ml 3.5ml twice<br />daily<br />3.5 ml once daily 5.0 ml<br />7.5 kg 22.5 mg 3.8 ml 3.8 ml twice<br />daily<br />3.8 ml once daily 5.0 ml<br />8 kg 24 mg 4.0 ml 4.0 ml twice<br />daily<br />4.0 ml once daily 5.0 ml</p><p>8.5 kg 25.5 mg 4.3 ml 4.3 ml twice<br />daily<br />4.3 ml once daily 5.0 ml<br />9 kg 27 mg 4.5 ml 4.5 ml twice<br />daily<br />4.5 ml once daily 5.0 ml<br />9.5 kg 28.5 mg 4.8 ml 4.8 ml twice<br />daily<br />4.8 ml once daily 5.0 ml<br />10 kg 30 mg 5.0 ml 5.0 ml twice<br />daily<br />5.0 ml once daily 5.0 ml<br />Dispense the pharmacy compounded suspension with a graduated oral syringe for measuring small<br />amounts of suspension. If possible, mark or highlight the graduation corresponding to the<br />appropriate dose (according to the dosing tables above) on the oral syringe for each patient.<br />The appropriate dose must be mixed by the caregiver with an equal quantity of sweet liquid food,<br />such as sugar water, chocolate syrup, cherry syrup, dessert toppings (like caramel or fudge sauce) to<br />mask the bitter taste.<br />Home preparation<br />When commercially manufactured Oselta oral suspension is not available, a pharmacy compounded<br />suspension prepared from Oselta capsules can be used (see detailed instructions above). If the<br />pharmacy compounded suspension is also not available, Oselta suspension may be prepared at<br />home. The pharmacy compounded suspension is the preferred option in infants less than 1 year of<br />age.<br />When appropriate capsule strengths are available for the dose needed, the dose is given by opening<br />the capsule and mixing its contents with no more than one teaspoon of a suitable sweetened food<br />product. The bitter taste can be masked by products such as sugar water, chocolate syrup, cherry<br />syrup, dessert toppings (like caramel or fudge sauce). The mixture should be stirred and given&nbsp;entirely to the patient. The mixture must be swallowed immediately after its preparation.<br />When only 75 mg capsules are available, and doses of 30 mg or 45 mg are needed, the preparation<br />of Oselta suspension involves additional steps. Detailed instructions can be found in the package<br />leaflet of Oselta capsules under &ldquo;Making Oselta suspension at home&rdquo;.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company Limited
P.O. Box 6267
Jeddah 21442
Tel: +966-12-6081111
Fax: +966-12-6081222.
Kingdom of Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                08 2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>